[Skip to Content]
[Skip to Content Landing]
Views 4,692
Citations 0
Editorial
July 2, 2019

Tanezumab for Painful Osteoarthritis

Author Affiliations
  • 1Department of Orthopedic Surgery, Division of Rheumatology, Immunology and Allergy, Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts
JAMA. 2019;322(1):30-32. doi:10.1001/jama.2019.8250

Osteoarthritis (OA) is a painful, disabling condition that arises from damage to cartilage, synovium, subchondral bone, and other joint structures. An estimated 300 million people worldwide have OA,1 including 30 million individuals in the United States,2 of whom more than 14 million have symptomatic, radiographically documented knee OA.3 Despite the enormous prevalence, cost, and disability associated with OA, no treatments are available to slow or reverse the inexorable destruction of joint structures that underlie the pain and disability of OA (although several agents are in various stages of evaluation, including strontium ranelate, sprifermin, and others).4 Thus, the primary objectives of contemporary OA therapy have been to control pain and improve physical functional status.

×